CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023

Posted: December 26, 2022 at 12:12 am

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it plans to outline its pipeline priorities for 2023 and provide a data update for the CX-2029 Phase 2 cohort expansion study, on Thursday, January 5, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss updates.

Go here to see the original:
CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023

Related Posts